The transition from accelerated to traditional approval is backed by robust 24-month eGFR data from the phase 3 APPLAUSE-IgAN trial.
Most ION events occurred in men, patients 50 years or older, with minimal risk seen in women, patients younger than 50 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results